• Explore /
  • Poster
  • / Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC): Cohort C of the phase 1b/2 KEYNOTE-365 study.

Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC): Cohort C of the phase 1b/2 KEYNOTE-365 study.

Abstract Poster

Authors

null

Peter C.C. Fong

Auckland City Hospital, Auckland, New Zealand

Peter C.C. Fong , Margitta Retz , Alexandra Drakaki , Christophe Massard , William R. Berry , Emanuela Romano , Johann S. De Bono , Susan Feyerabend , Leonard Joseph Appleman , Henry Jacob Conter , Srikala S. Sridhar , Neal D. Shore , Mark David Linch , Anthony M. Joshua , Howard Gurney , Helen Wu , Charles Schloss , Christian Heinrich Poehlein , Evan Y. Yu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Genitourinary (Prostate) Cancer

Track

Genitourinary Cancer—Prostate, Testicular, and Penile

Sub Track

Prostate Cancer - Advanced Disease

Clinical Trial Registration Number

NCT02861573

Citation

J Clin Oncol 37, 2019 (suppl; abstr 5010)

DOI

10.1200/JCO.2019.37.15_suppl.5010

Abstract #

5010

Poster Bd #

122

Abstract Disclosures

Similar Posters

First Author: William R. Berry

First Author: Christophe Massard

First Author: Peter C.C. Fong

First Author: Christophe Massard